Article
Author(s):
Baltimore-All phakic IOLs are associated with potential problems, although evolution in implant design has been accompanied by declining complication rates, said Walter J. Stark, MD.
Glaukos announces several positive clinical updates for its iDose platform
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
InflammX Therapeutics enters option agreement with Bausch + Lomb, grants right to acquire the company
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
Inflammasome Therapeutics expands K8 trial following positive 3-month results